Method and device for determining cerebral ischemia characteristic based on magnetic resonance diffusion-weighted image

Abstract

A method and an apparatus for determining brain ischemia features on the basis of magnetic resonance diffusion-weighted imaging (DWI), so as to provide an objective basis for determining whether to apply a thrombolytic therapy to an acute brain ischemia patient. The method comprises: determining a brain ischemia area of a to-be-detected patient according to magnetic resonance DWI of the to-be-detected patient, the brain ischemia area comprising a core area and a transition area; determining, according to DWI values of the core area and the transition area, an apparent diffusion coefficient (ADC) feature parameter ADC r in an area with a high DWI value in the magnetic resonance DWI; and determining, according to the ADC feature parameter ADC r, whether an ADC value in the area with a high DWI value is mismatched with the area with a high DWI value. With this method, it is more scientific and objective to make a decision whether to apply a thrombolytic therapy to a brain ischemia patient, thereby improving the cure rate of the brain ischemia patient.

Description

technical field [0001] The invention relates to the field of biomedical images, in particular to a method and a device for determining cerebral ischemia characteristics based on magnetic resonance diffusion weighted imaging. Background technique [0002] In China, the incidence of cerebrovascular disease is increasing year by year. The results of epidemiological surveys in recent years show that cerebrovascular disease ranks second in the cause of death in China after malignant tumors. Cerebrovascular disease has a high disability rate and seriously endangers human health and quality of life. Among them, ischemic stroke (cerebral infarction) accounts for more than 70% of all cerebrovascular diseases. Therefore, it is particularly important to strengthen the research on cerebral infarction. [0003] For ischemic stroke, the guidelines of various countries recommend intravenous recombinant tissue-type plasminogen activator (rtPA) thrombolytic therapy as the first choice at th...

AI Technical Summary

Problems solved by technology

In other words, the existing method for guiding thrombolysis in patients with acute cerebral ischemia is not based on the precise grasp of the characteristics of the patient's cerebral ischemia, so this method still has shortcomings

Images